Search results for " BsAbs"
Article
2019’s Top Bioprocessing Trends and What to Expect in 2020
2019 proved to be an exciting year for biopharmaceutical developers and process engineers, filled with both advancements and lessons. Considering how far the industry has come, what direction will 2…
Article
Purification strategies for antibody-derived entities: bispecifics and fragments
The diversity of antibody variants in today’s pipeline presents unique challenges for purification. Purification platforms used for many monoclonal antibodies (mAbs) need to be adopted for ant…
Article
Chromatography processes for the diversified therapeutic antibody pipeline
The diversity of antibody variants in today’s pipeline presents unique challenges for purification and we see molecules such as bsAbs, Fabs, dAbs, and others. Conventional chromatography protocols, …
Article
As the therapeutic pipeline diversifies, chromatography toolboxes are expanding.
Development beyond traditional monoclonal antibodies (mAbs) is increasing, and today, we see antibody variants like multispecific and bispecific antibodies and antibody fragments. In mAb proc…
Article
Antibody purification quiz
Test your knowledge and gain insights in the purification of antibody variants – bsAbs, Fab, dAbs.
Article
Capture of Bispecific Antibodies and Removal of Product-Related Impurities
The biotherapeutics pipeline is becoming increasingly diverse as antibody variants such as bispecifics, conjugates, and fragments move through preclinical stages to commercial manufacturin…
Article
Bispecific Antibodies are Moving from Research to Clinical Development
With recent approvals of bispecific antibodies, these complex molecules are fast moving out of the research box and into clinical pipelines.
READ MORE >>
Article
Bispecific Antibody Purification: Insights and Case Studies
New modalities, like bispecific antibodies, present unique challenges compared to mAb production. For purification, there’s not just one right answer to which strategy to use. Here are some industry…